Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
US Department of Justice
Express Scripts
McKesson
Dow
Teva
Moodys
McKinsey
Argus Health
Novartis

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,772,353

« Back to Dashboard

Which drugs does patent 8,772,353 protect, and when does it expire?


Patent 8,772,353 protects OSPHENA and is included in one NDA.

This patent has twenty-four patent family members in nineteen countries.

Summary for Patent: 8,772,353

Title:Method for enhancing the bioavalability of ospemifene
Abstract: This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) ##STR00001## or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.
Inventor(s): Anttila; Markku (Turku, FI)
Assignee: Hormos Medical Ltd. (Turku, FI)
Application Number:13/904,818
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
DuchesnayOSPHENAospemifeneTABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
DuchesnayOSPHENAospemifeneTABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,772,353

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,236,861Method for enhancing the bioavailablity of ospemifene► Subscribe
9,241,915Method for enhancing the bioavailability of ospemifene► Subscribe
8,470,890Method for enhancing the bioavailability of ospemifene► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,772,353

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia1713458► Subscribe
Russian Federation2385716► Subscribe
Russian Federation2006132719► Subscribe
Portugal1713458► Subscribe
Norway339190► Subscribe
Norway20151603► Subscribe
Norway337656► Subscribe
Norway20063960► Subscribe
MexicoPA06009274► Subscribe
Luxembourg92736► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Deloitte
Merck
Dow
Queensland Health
Healthtrust
Chubb
Teva
Daiichi Sankyo
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot